Article ; Online: Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
2017 Volume 52, Issue 3, Page(s) 251–256
Abstract: Background: There is no established method for monitoring the anticoagulant effects of apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has been shown, with r: Objective: To evaluate the anti-Xa activity and ... ...
| Abstract | Background: There is no established method for monitoring the anticoagulant effects of apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has been shown, with r Objective: To evaluate the anti-Xa activity and serum levels at those doses and compare the trough anti-Xa activity. Methods: This was a single-center prospective study,approved by the institutional review board. Patients on an inappropriate dose or receiving an interacting drug were excluded. Blood samples were drawn 0.5 to 3 hours before a dose for both agents, 2 to 3 hours after an apixaban dose, and 12 to 16 hours after a rivaroxaban dose. Anti-Xa activity and serum levels were determined, and correlation was done via regression analysis. Trough anti-Xa activity was compared using a t-test. Results: The study enrolled 88 patients receiving each drug. The r Conclusions: Good correlation was shown between anti-Xa activity and serum levels. The clinical utility of monitoring anti-Xa activity and the significance of the difference in trough anti-Xa activity for these agents remains to be established. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Aged ; Factor Xa/analysis ; Factor Xa Inhibitors/blood ; Factor Xa Inhibitors/pharmacokinetics ; Factor Xa Inhibitors/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Pyrazoles/blood ; Pyrazoles/pharmacokinetics ; Pyrazoles/therapeutic use ; Pyridones/blood ; Pyridones/pharmacokinetics ; Pyridones/therapeutic use ; Rivaroxaban/blood ; Rivaroxaban/pharmacokinetics ; Rivaroxaban/therapeutic use | |||||
| Chemical Substances | Factor Xa Inhibitors ; Pyrazoles ; Pyridones ; apixaban (3Z9Y7UWC1J) ; Rivaroxaban (9NDF7JZ4M3) ; Factor Xa (EC 3.4.21.6) | |||||
| Language | English | |||||
| Publishing date | 2017-10-19 | |||||
| Publishing country | United States | |||||
| Document type | Clinical Trial ; Journal Article | |||||
| ZDB-ID | 1101370-9 | |||||
| ISSN | 1542-6270 ; 1060-0280 | |||||
| ISSN (online) | 1542-6270 | |||||
| ISSN | 1060-0280 | |||||
| DOI | 10.1177/1060028017738262 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 900: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.